Diabetes Mellitus, Type 2
Conditions
Keywords
Blood glucose, Diabetes Mellitus, Type 2, Lactulose, Constipation, Oral intake
Brief summary
The objective of the study is to investigate whether lactulose, given orally as powder or liquid, increases blood glucose levels in patients with diabetes mellitus type 2. The dose of lactulose given in the study is normally used for treatment of constipation.
Interventions
White or almost white crystalline powder. The product will be provided in sachets to be dissolved in 250 mL water.
DRUGLactulose crystals 30 g
White or almost white crystalline powder. The products will be provided in sachets to be dissolved in 250 mL water.
Clear, viscous liquid, colourless or pale brownish-yellow liquid syrup (solution). The products will be provided in sachets to be dissolved in 250 mL water.
DRUGLactulose liquid 30 g
Clear, viscous liquid, colourless or pale brownish-yellow liquid syrup (solution). The products will be provided in sachets to be dissolved in 250 mL water.
DRUGGlucose
White crystalline powder. To standardise for 30 g glucose, 33 g glucose monohydrate will be used. The products will be provided in sachets to be dissolved in 250 mL water.
DRUGStill water
250 mL still water will be used. Water from the same source will be also used to dissolve investigational and control products
Sponsors
Fresenius Kabi
Study design
Allocation
RANDOMIZED
Intervention model
CROSSOVER
Primary purpose
BASIC_SCIENCE
Masking
DOUBLE (Subject, Investigator)
Eligibility
Sex/Gender
ALL
Age
18 Years to 75 Years
Healthy volunteers
No
Inclusion criteria
1. Patients with non-insulin requiring diabetes mellitus type 2 treated with diet and oral antidiabetics and/or Glucagon-like Peptide 1 receptor agonists 2. Age: 18-75 years 3. Female and male 4. Caucasian 5. HbA1c ≤ 7.5 % 6. Stable treatment, i.e. no change in diabetes mellitus related medication within the last 3 months 7. Mild functional constipation according to modified Rome IV criteria fulfilled for the last 3 months with symptom onset at least 6 months before study start defined as: * approx. 3-5 bowel movements per week, * of which 1-2 usually cause discomfort e.g., straining, lumpy or hard stools, sensation of incomplete evacuation or anorectal obstructions/blockage 8. Availability and presence in the trial unit for approx. 4 hours/ week for 4 weeks 9. Women of childbearing potential must be using a medically approved method of contraception OR women must be postmenopausal for at least 12 months prior to study entry 10. Signed informed consent form
Exclusion criteria
1. Fasting blood glucose \<4.4 mmol/L (\<80 mg/dL) or \>10 mmol/L (\>180 mg/dL) (capillary) 2. BMI \<18.5 kg/m² or ≥35 kg/m² 3. Change in body weight ≥10 % within the last 3 months 4. Smoker 5. Major medical or surgical event requiring hospitalization within the last 3 months 6. Acute gastrointestinal diseases including diarrhea and/or vomiting within the last 2 weeks 7. Presence of disease or intake of drug(s) / supplements other than antidiabetic treatment influencing digestion and absorption of carbohydrates or bowel habits (intake of laxatives in general allowed with exception see next criterion) (dietary / supplementary fibres allowed if stable dose since 1 month before study start) 8. Not willing to abstain from laxatives 2 days before the visits 1-4 and up to 24h after visits 1-4 9. Use of following medication/ supplementation within the last 4 weeks and during the study: * Intake of medications other than antidiabetic treatment known to affect glucose tolerance e.g., steroids, protease inhibitors or antipsychotics; * Intake of prebiotics or probiotics * Chronic intake of substances affecting blood coagulation (e.g. acetylic acid (100 mg as standard prophylactic treatment allowed when dose is stable 1 month prior to screening), anticoagulants, diuretics, thiazides (diuretics and thiazides allowed e.g. for hypertension treatment when dose is stable 1 month prior to screening)), which in the investigator's opinion would impact patient safety 10. Severe liver, renal or cardiac disease 11. Hereditary problems of galactose or fructose intolerance, lactase deficiency or glucose-galactose malabsorption 12. Suspicion of alcohol abuse (defined as an average daily intake of more than one litre of beer per day or equivalent amount of alcohol in other beverages) or drug abuse 13. Known or suspected allergy to the investigational drug(s) or other components of the study drug(s) 14. Acute inflammatory bowel disease (ulcerative colitis, Crohn's disease), gastrointestinal obstruction or subocclusive syndrome, perforations or risk of perforation in gastrointestinal tract, abdominal pain of undetermined cause 15. Known history of human immunodeficiency virus (HIV), hepatitis B and/or C 16. Pregnancy, lactation 17. Clinically relevant findings as established by medical history, physical examination, clinical laboratory and/or vital signs 18. Participation in another interventional study with an investigational drug or an investigational medical device within 30 days prior to start of study or during the study
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Capillary blood glucose levels as baseline corrected AUC: AUCbaseline_c (0-180 minutes) [Baseline corrected area under curve from 0 to 180 minutes for blood glucose concentration (= Area under curve from 0 to 180 minutes minus baseline*180 minutes)] | 0 - 180 minutes, during 4 study visits |
Secondary
| Measure | Time frame |
|---|---|
| Maximum increase of blood glucose concentration (Max_increase) | 0 - 180 minutes, during 4 study visits |
| Relative maximum increase of blood glucose concentration (Max_increase_rel) | 0 - 180 minutes, during 4 study visits |
| Time to reach maximum blood glucose concentration (Tmax) | 0 - 180 minutes, during 4 study visits |
| Total area under curve from 0 to 180 minutes for blood glucose concentration (AUC(0-180 minutes)) | 0 - 180 minutes, during 4 study visits |
| Incremental area under curve from 0 to 180 minutes for blood glucose concentration, i.e., above baseline levels for blood glucose concentration after oral intake of Laevolac crystals/liquid or control products (iAUC(0-180min)) | 0 - 180 minutes, during 4 study visits |
| Maximum blood glucose concentration (Cmax) | 0 - 180 minutes, during 4 study visits |
Other
| Measure | Time frame | Description |
|---|---|---|
| Gastrointestinal tolerability: diarrhoea, distension, rumbling, nausea, vomiting, burping, regurgitation/heartburn, flatulence, abdominal discomfort, abdominal pain | 180 minutes and 24 hours post-dose | The single gastrointestinal symptoms will be assessed by the patients using a 4-point Likert scale: No symptoms or discomfort, Mild symptoms or discomfort, Moderate symptoms of discomfort, or Severe symptoms of discomfort. |
| Blood glucose concentration at 240 minutes - only when blood glucose is >10 mmol/L (>180 mg/dL) at 180 minutes | 240 minutes post-dose | — |
| Gastrointestinal tolerability: global scaled evaluation | 180 minutes and 24 hours post-dose | Gastrointestinal tolerability will be assessed by the patients by means of a global scaled evaluation with Very good, Good, Moderate, or Poor. |
| Adverse Events (AEs) | up to 64 days | Adverse Events will be documented from start of fasting on the day before Screening until the day after the last study Intervention. This is up to 64 days, depending on the day of Screening (21 to 3 days before the first study Intervention) and on the duration of wash out phases between interventions. |
Countries
Austria
Outcome results
None listed